Efficacy on Height in SGA Children Treated With Growth Hormone
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
3 Years to 7 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Born small for gestational age with length and/or weight at -2 SDS or below at time of birth, according to country specific references.
Severe growth failure with no catch up and with height at -2.5 SDS or below, according to country specific references, for chronological age at time of inclusion
Growth Hormone Deficiency (GHD)
Treatment with any medical product which may interfere with GH effects
Growth retardation associated with infections, severe chronic diseases including chromosomal anomaly or nutritional disorders
Phillip M, Lebl J, Zuckerman-Levin N, Korpal-Szczyrska M, Sales Marques J, Ibáñez L on behalf of the European Norditropin SGA study group. Multinational study in short SGA children: evaluation of the effect of three different growth hormone dose regimens. European Society for Paediatric Endocrinology (ESPE) 2007; Country: Finland City: Helsinki